<DOC>
	<DOCNO>NCT01791894</DOCNO>
	<brief_summary>This pilot clinical trial study arsenic trioxide treat patient basal cell carcinoma . Drugs use chemotherapy , arsenic trioxide , work different way stop growth tumor cell , either kill cell stop dividing</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Basal Cell Carcinoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether administration arsenic trioxide ( ATO ) patient basal cell carcinoma associate reduction Gli messenger ribonucleic acid ( mRNA ) protein level tumor biopsy sample , compare baseline level . SECONDARY OBJECTIVES : I . To determine whether evidence tumor size reduction ATO basal cell carcinoma human . OUTLINE : Patients receive arsenic trioxide intravenously ( IV ) 2 hour day 1-5 . Courses repeat every 28 day absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Basal Cell</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Patients basal cell carcinoma ( BCC ) Patients ineligible curative locoregional treatment either progress , tolerate , unwilling try ineligible investigational smoothen antagonist vismodegib ( GDC 0449 ) , XL 139 ( BMS 833923 ) , IPI 926 , LDE225 PF04449913 Life expectancy estimate &gt; 3 month Performance status Eastern Cooperative Oncology Group ( ECOG ) 02 Absolute neutrophil count &gt; = 1,500/mcL Platelets &gt; = 100,000/mcL Total bilirubin within normal institutional limit Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 x institutional upper limit normal Creatinine within normal institutional limit Corrected QT interval ( QTC ) 12 lead electrocardiogram ( EKG ) &lt; 450 msec Serum potassium within normal limit Magnesium within normal limit Calcium within normal limit Include follow : ability understand willingness sign write informed consent document Patients must evaluable tumor potentially eligible pre post ATO tumor biopsy Concurrent use Investigational agent prohibit Patients cardiac arrhythmia exclude Patients receive potassium waste diuretic amphotericin , exclude , must note theoretically increased arrhythmia risk ATO Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , recurrent seizure history psychiatric illness/social situation would limit compliance study requirement Pregnant woman breastfeed woman exclude study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>